Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting

Status Terminated

Clinical Trial Summary

RATIONALE: Rosiglitazone may help pituitary tumor cells become more like normal cells, and to grow and spread more slowly.

PURPOSE: This phase II trial is studying how well rosiglitazone works in treating patients with newly diagnosed ACTH-secreting pituitary tumor (Cushing disease).

Clinical Trial Description

OBJECTIVES:

Primary

- To assess the effect of rosiglitazone on biochemical control in patients with newly diagnosed ACTH-secreting pituitary tumor (Cushing disease).

Secondary

- To assess the effect of this drug on corticotrophin (CRH)-stimulated pituitary tumor ACTH secretion.

- To assess the overall safety and tolerability of this drug in these patients.

- To assess the overall quality of life of patients treated with this drug.

- Percentage of Reduction in 24-hour Urinary-free Cortisol Levels

OUTLINE: This is a multicenter study.

Patients receive oral rosiglitazone once daily for 7 weeks in the absence of disease progression or unacceptable toxicity.

Blood, urine, and saliva samples are collected periodically for laboratory studies. Inflammatory markers (C-reactive protein, interleukin-6 [IL-6], serum sialic acid, soluble intracellular and vascular adhesion molecules [sICAM-1, and sVCAM-1], and amyloid A) are measured at baseline and at the completion of study treatment; salivary cortisol and 24-hour urinary-free cortisol levels are measured at baseline and weekly during study treatment; dexamethasone suppression tests with serum cortisol and corticotrophin (CRH) stimulation test are performed at baseline and at the completion of study treatment; prolactin, insulin-like growth factor-1 (IGF1), thyroid function, and sex steroid hormones are measured at baseline and at the completion of study treatment; and dynamic pituitary function testing (arginine/growth hormone-releasing hormone [GHRH] testing to measure growth hormone secretion) is performed at baseline. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00612066
Study type	Interventional
Source	Jonsson Comprehensive Cancer Center
Contact
Status	Terminated
Phase	Phase 2
Start date	April 2007
Completion date	November 2010

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT00881283` - Long-term Cardiovascular Risk in Cured Cushing's Patients
Completed	`NCT02568982` - Cushing's Disease Complications
Completed	`NCT02697734` - Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease	Phase 3
Completed	`NCT01374906` - Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease	Phase 3
Recruiting	`NCT03364803` - Collecting Information About Treatment Results for Patients With Cushing's Syndrome
Not yet recruiting	`NCT02603653` - Assessment of Persistent Cognitive Impairment After Cure of Cushing's Disease	N/A
Completed	`NCT01371565` - Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome	Phase 3
Recruiting	`NCT00845351` - Preoperative Bexarotene Treatment for Cushing's Disease	Phase 1/Phase 2
Completed	`NCT00889525` - Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor	Phase 3
Completed	`NCT02060383` - Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly	Phase 4
Recruiting	`NCT03474601` - Seoul National University Pituitary Disease Cohort Study
Recruiting	`NCT02484755` - Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease	Phase 2
Recruiting	`NCT04339751` - Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease	Phase 2
Not yet recruiting	`NCT04569591` - Corticotrophin-releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing s Disease	N/A
Completed	`NCT01794793` - Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies	Phase 4
Completed	`NCT00434148` - Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease	Phase 3
Completed	`NCT03346954` - Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease	N/A
Withdrawn	`NCT01925092` - Mifepristone in Children With Refractory Cushing's Disease	Phase 3
Completed	`NCT01582061` - An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.	Phase 3
Recruiting	`NCT03708900` - Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Disease	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms